Tag Archives: CEO
Asbestos Mining Company CEO Defends Industry
Bernard Coulombe, president and chief executive officer of the Canadian asbestos extraction giant Mine Jeffrey, defended his company and the asbestos industry against charges of failing to provide proper safety measures for workers in the country’s chrysotile mines and concrete mixing plants. With increased pressure from public health officials, environmental activists and government agencies in [...]
New Lung Cancer Drug Starts Phase II Clinical Trial
An experimental drug which could possibly help patients undergoing treatment for non-small cell lung cancer (NSCLC) has moved into Phase II clinical trials, according to a joint report from the drug manufacturer CanBas Co., Ltd., of Shizuoka, Japan, and Takeda Pharmaceutical Company Ltd., of Osaka, Japan, the two companies working together on the development of [...]
Pennsylvania Town Receives Additional Funding for Asbestos Cleanup
Ambler, PA – On Feb 22, 2009, State Senator Stewart Greenleaf, R-12th District, presented a check for $1 million to two businessmen who seek to redevelop the old Keasbey and Mattison (KM) site on South Maple Street in Ambler. John Westrum, CEO of Westrum Development, and John Zaharchuk of Summit Realty, added Greenleaf’s funds to [...]
Asbestos Contaminated Ship Faces Protesters in Great Britain
HARTLEPOOL, UK – Environmental activists in England are vigorously protesting the imminent arrival of the asbestos-contaminated, French aircraft carrier, Clemenceau, which is scheduled to be dismantled at the Northern England shipyard at Hartlepool. Environmentalists point to the fact that the French ship, now known simply as Hull Q790, was turned away by India in 2006 [...]
Attacking Cancer Stem Cells a Way to Treat Cancer
A new cancer treatment is on the horizon since scientists made a breakthrough discovery in the understanding of how tumor cells grow. The basis of the treatment is that a tiny portion of cancer cells, which have been named cancer stem cells, is the cause of the malignant nature of tumors. It is still controversial, [...]
INNOVIVE Pharmaceuticals Begins Enrollment in Phase I Study of INNO-305 Peptide Immunotherapy in AML, MDS, Mesothelioma and Non-Small Cell Lung Cancer
Source: INNOVIVE Pharmaceuticals, Inc., October 27, 2006 INNOVIVE Pharmaceuticals, Inc., a biopharmaceutical company headquartered in Manhattan, announced today that a Phase I clinical trial investigating INNO-305 in acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), mesothelioma and non-small cell lung cancer (NSCLC) has enrolled its first patient. The trial is being conducted by Lee Krug, M.D., [...]
